Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Eli Lilly will likely give it a brand name (similar to how tirzepatide became "Mounjaro" and "Zepbound" for different indications)
(2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist Cell Metab 34(9):1234-1247
Pricing was set at $149 per month for self-pay patients, $25 with commercial insurance, and $50 for Medicare beneficiaries starting July 1
We do not use research chemicals or unregulated products
Although its full physiological role remains unknown, enhancement of glucagon secretion and impairment of insulin secretion in response to GIP administration hinders the development of mono-GIP-directed therapies
As of 2025, retatrutide has not received a UK marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), which is the licensing authority for Great Britain
.jpg)
